Geron (GERN) Long-Term Investments (2010 - 2026)
Geron (GERN) posted Long-Term Investments of $26.7 million for Q1 2026, down 35.37% sequentially from $41.3 million in Q4 2025, and down 54.61% YoY from $58.8 million in Q1 2025.
Geron (GERN) Long-Term Investments (2010 - 2026) Analysis & Trends
Geron has reported Long-Term Investments for 16 years, with the latest figure at $26.7 million in Q1 2026.
- Quarterly Long-Term Investments fell 54.61% year-over-year to $26.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.7 million (down 54.61% YoY) and the FY2025 annual result came in at $41.3 million, down 56.32% from the prior year.
- Long-Term Investments eased to $26.7 million in Q1 2026 per GERN's latest filing, from $41.3 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $94.5 million in Q4 2024 and troughed at $364000.0 in Q2 2022.
- A 5-year average of $27.8 million and a median of $26.7 million in 2026 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2022 and 2023: Long-Term Investments sank 99.1% in 2022, then surged 18532.14% in 2023.
- Over 5 years, Long-Term Investments stood at $364000.0 in 2022, then surged by 206.32% to $1.1 million in 2023, then surged by 8377.04% to $94.5 million in 2024, then sank by 56.32% to $41.3 million in 2025, then tumbled by 35.37% to $26.7 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $26.7 million, $41.3 million, and $39.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - | 24.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.12 Mn |
| Mar 31, 2026 | 26.69 Mn |
| Dec 31, 2025 | 41.29 Mn |
| Sep 30, 2025 | 39.06 Mn |
| Jun 30, 2025 | 42.74 Mn |
| Mar 31, 2025 | 58.80 Mn |
| Dec 31, 2024 | 94.52 Mn |
| Sep 30, 2024 | 37.31 Mn |
| Jun 30, 2024 | 1.12 Mn |
| Mar 31, 2024 | 20.78 Mn |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 67.82 Mn |
| Jun 30, 2023 | 535,000.00 |
| Mar 31, 2023 | 28.10 Mn |
| Dec 31, 2022 | 364,000.00 |
| Sep 30, 2022 | 364,000.00 |
| Jun 30, 2022 | 364,000.00 |
| Mar 31, 2022 | 10.95 Mn |
| Dec 31, 2021 | 28.65 Mn |
| Sep 30, 2021 | 39.36 Mn |